

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 February 2006 (02.02.2006)

PCT

(10) International Publication Number
WO 2006/012176 A1

- (51) International Patent Classification⁷: **C07D 413/06**
- (21) International Application Number:
PCT/US2005/022178
- (22) International Filing Date: 23 June 2005 (23.06.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/582,076 24 June 2004 (24.06.2004) US
- (71) Applicant (for all designated States except US): **VIRGINIA COMMONWEALTH UNIVERSITY** [US/US]; 800 East Leigh Street, Suite 113, Richmond, VA 23219 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **MARTIN, Billy, R.** [US/US]; 2406 St. Regis Drive, Richmond, VA 23236 (US). **RAZDAN, Raj, K.** [US/US]; 34 Salt Island Road, Gloucester, MA 01930 (US). **MAHADEVAN, Anu** [US/US]; 14 Casie Lane, Westford, MA 01886 (US).
- (74) Agents: **WHITHAM, Michael, E.** et al.; Whitham, Curtis & Christofferson P.C., 11491 Sunset Hills Road, Suite 340, Reston, VA 20190 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: WATER-SOLUBLE CANNABINOIDS

(57) Abstract: Water-soluble cannabinoid compounds that are agonists of CB₁ and CB₂ cannabinoid receptors are provided. The compounds are made water-soluble by derivatization of the alkyl side chain and/or the phenolic hydroxyl group of tetrahydrocannabinol. The water-soluble cannabinoids are useful for the treatment of appetite loss, pain, multiple sclerosis, nausea and vomiting, and epilepsy.

WO 2006/012176 A1

WATER-SOLUBLE CANNABINOID

DESCRIPTION

BACKGROUND OF THE INVENTION

Field of the Invention

5 The invention generally relates to water-soluble cannabinoid agonists. In particular, the invention provides water-soluble cannabinoid compounds that are agonists of CB₁ and CB₂ receptors, and that are useful for treating or alleviating a number of disorders of symptoms thereof, including, for example, appetite loss, pain, multiple sclerosis, nausea and vomiting, and epilepsy.

Background of the Invention

10 Marijuana has attracted considerable attention for centuries because of its psychotropic and medicinal properties. Early scientific investigations were conducted with either smoked plant material or the plant extract. Needless to say, the synthesis of marijuana's major psychotropic constituent, Δ^9 -THC, opened a new era in marijuana
15 research (Gaoni and Mechoulam, 1964). For the first time researchers were able to conduct research in a quantitative fashion, because the precise dose of Δ^9 -THC could be administered. Unfortunately, Δ^9 -THC is a non-crystalline, highly lipophilic compound that requires solubilization with either a surfactant agent or adherence to a water miscible
20 substance (albumin, Tween 80, etc.). Even under these circumstances, Δ^9 -THC is sometimes capable of adhering to solid surfaces rather than remaining in solution. This high
lipophilicity has placed constraints on the pharmacological evaluation of Δ^9 -THC. There is always the concern that the use of different vehicles in separate pharmacological studies may influence the pharmacological effects of Δ^9 -THC. It is for these reasons that there have been numerous attempts to prepare water-soluble derivatives of cannabinoids.

25 The first successful attempt in preparing a water-soluble form of Δ^9 -THC involved converting it to a morpholinobutyl ester, the hydrochloride of which was water-soluble (Zitko et al., 1972). This compound retained cannabinoid pharmacological activity. A

morpholinobutyl ester of Δ^8 -THC was also found to be equipotent to Δ^8 -THC in several behavioral models (Compton and Martin, 1990). Water-soluble derivatives of THC were prepared in other laboratories and found to be effective in lowering intraocular pressure in rabbits (ElSohly et al., 1984). In more recent times, numerous cannabinoid analogs have been developed that are considerably more potent than Δ^9 -THC (Martin et al., 1999; Khanolkar et al., 2000). One of these compounds contains a cyano group on the terminal carbon atom of the side chain in Δ^8 -THC (Martin et al., 1999). Therefore, a morpholinobutyl ester of this potent cannabinoid was prepared and found to be highly active when prepared in saline and evaluated either *in vivo* or *in vitro* (Pertwee et al., 2000). It is assumed that these phenolic esters (Zitko et al., 1972; Pertwee et al., 2000) are prodrugs, because a free hydroxyl group is required for pharmacological activity of Δ^9 -THC at the CB₁ cannabinoid receptor (Razdan, 1986; Huffman et al., 2002). Phosphate esters of the endocannabinoids anandamide and noladin ether have also been prepared (Juntunen et al., 2003a; Juntunen et al., 2003b). These esters are rapidly hydrolyzed in biological tissues and are effective in lowering intraocular pressure in rabbits when applied in an aqueous solution.

There have also been numerous attempts to prepare analogs with reduced lipophilicity. Early receptor binding studies conducted with radiolabeled Δ^8 -THC were of limited success because of the extensive non-specific binding by this highly lipophilic agent (Harris et al., 1978). In an effort to reduce non-specific binding, Nye et al. (Nye et al., 1988) prepared a radiolabeled trimethylammonium analog of Δ^8 -THC. This charged analog allowed them to label a specific binding site in brain, although it remains to be established that this site is a true cannabinoid receptor. A nitrogen mustard analog of Δ^9 -THC was found to be behaviorally active when administered centrally but not when administered peripherally, possibly due to reduced lipophilicity (Little et al., 1987).

There is thus an ongoing need to provide water-soluble cannabinoid compounds exhibiting high CB₁ and CB₂ receptor affinity and high bioavailability.


SUMMARY OF THE INVENTION

The invention provides water-soluble cannabinoid compounds with high CB₁ and CB₂ receptor affinity and high bioavailability. The compounds result from structural alterations in tetrahydrocannabinol for the purpose of increasing its water solubility and/or

miscibility. By making structural alterations in the alkyl side chains and at the phenolic hydroxyl group of tetrahydrocannabinol, a series of analogs have been prepared that are soluble and/or miscible in water, and which show high bioavailability. The analogs exhibit high affinity for the CB₁ and CB₂ receptors, and are thus water-soluble cannabinoid agonists.


The compounds are useful for treating diseases and disorders related to CB₁ and CB₂ receptor function, including appetite loss, nausea and vomiting, pain, multiple sclerosis and epilepsy. The agents are also valuable as research tools for scientists. In addition, novel analogs that are not water soluble but that exhibit high levels of CB₁ and CB₂ receptor affinity and *in vivo* activity are provided.

It is an object of this invention to provide water-soluble cannabinoid analogs with the general structure




wherein R₁ is H or a straight-chained, branched or cyclic C₁-C₆ lower alkyl; and R₂ is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N; or wherein R₂ is NR₃ where R₃ is H₂, H₃⁺, or mono or dialkyl C₁-C₆. Salts of such compounds are also contemplated. In one embodiment, the 5-7 membered heterocyclic ring may be, for example, piperidine, methyl piperidine, methyl piperazine or morpholine.

The invention also provides cannabinoid analogs with the general structure




in which R_4 is an azole or morpholine ring. Salts of these compounds are also provided. In one embodiment, the azole ring may be, for example, imidazole, 1H-imidazole, methyl imidazole, pyrazole, and triazole. In another embodiment, the cannabinoid analog is a water-soluble salt and the azole ring may be, for example, imidazole 1H-imidazole, methyl imidazole.

The invention also provides cannabinoid analogs with the general structure




in which R_5 is NH_2 , $NHCH_3$, or NHR_6 , and R_6 is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N. Alternatively, R_5 may be a 5-7 membered heterocyclic ring in which at least one of the member atoms is N. Salts of such compounds are also provided. In a preferred embodiment of the invention, R_6 is a heterocyclic ring such as, for example, morpholine, homo-piperidine, pyrrolidine, or piperidine. In another embodiment, R_5 is a heterocyclic ring such as, for example, morpholine, piperidine, piperazine, pyrrolidine, or homo-piperidine.

The invention also provides water-soluble cannabinoid analogs with general structure




in which R_7 is H or a straight-chained, branched or cyclic C_1 - C_6 lower alkyl (e.g. CH_3); and R_8 is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N; or


NR₃ where R₃ is H₂, H₃⁺, or mono or dialkyl C₁-C₆; and wherein R₉ is NH₂, NHCH₃, or NHR₆, where R₆ is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N. Alternatively, R₉ may be a 5-7 membered heterocyclic ring in which at least one of the member atoms is N. Salts of such compounds are also contemplated. In a preferred embodiment of the invention, the water-soluble cannabinoid is




In addition, a cannabinoid analog with the general structure




is provided. In this embodiment of the invention, R₁ = H, -COCHR₃-CH₂-CH₂-R₄ and R₂ = CN or COR₇, where: R₃ = H, straight-chained, branched or cyclic C₁-C₆ lower alkyl; R₄ and R₇ may be the same or different and are: NH₂, NHCH₃, N(R₈)₂ (where R₈ = COR₇); a 5-7 membered heterocyclic ring with at least one N atom; or NHR₅ (where R₅ is a 5-7 membered heterocyclic ring with one N atom). In a preferred embodiment, the 5-7 membered heterocyclic ring is



The invention also provides a method of treating or alleviating symptoms of a disease or disorder associated with CB1 and CB2 cannabinoid receptors in a patient in need thereof. The method comprises the step of administering to the patient a compound (or salt thereof) of a general structural formula:



- 5 in which $R_1 = H$, $-COCHR_3-CH_2-CH_2-R_4$ and $R_2 = CN$ or COR_7 , where: $R_3 = H$, straight-chained, branched or cyclic C_1-C_6 lower alkyl; R_4 and R_7 may be the same or different and are: NH_2 , $NHCH_3$, $N(R_8)_2$ (where $R_8 = COR_7$); a 5-7 membered heterocyclic ring with at least one N atom; or NHR_5 (where R_5 is a 5-7 membered heterocyclic ring with one N atom). In a preferred embodiment, the 5-7 membered heterocyclic ring is



BRIEF DESCRIPTION OF THE DRAWINGS

- 10 **Figure 1.** General synthesis scheme for compounds of the present invention.
Figure 2. Synthesis Scheme 1 for selected compounds shown in Table 3 (e.g. **16a-e**, **17a-e**).
Figure 3. Synthesis Scheme 2 for selected compounds shown in Table 1 (e.g. **7a-g**).
Figure 4. Synthesis Scheme 3 for selected compounds shown in Table 1 (e.g. **5c-f**).
Figure 5. Synthesis Scheme 4 for selected compounds shown in Table 2 (e.g. **5h**, **5j-m**, **7r**).
15 **Figure 6.** Synthesis Scheme 5 for **7m**, shown in Table 4.
Figure 7. Effects of O-2426 (0.1 mg/kg) or saline administered i.v. at different time points before testing. The ED50 of O-2426 after i.v. administration is 0.05, 0.04, 0.10 and 0.11 μ moles/kg in spontaneous activity, tail-flick response, rectal temperature and relative immobility, respectively. Therefore a time course was determined using a dose of 0.1 mg/kg
20 (0.16 μ moles/kg). The data in the figure show that the sedative effects of this ester have

disappeared by one hour but the other effects remain. All effects are gone by 2 hours.

Figure 8. Time course of O-2486 (1mg/kg) or saline after i.v. administration at different time points before testing. The ED₅₀'s of O-2486 after i.v. administration are 0.05, 0.20, 1.7, and 0.6 μ moles/kg in spontaneous activity, tail-flick, rectal temperature and relative immobility, respectively. Therefore, a dose of 1 mg/kg (1.6 μ moles/kg) was chosen to determine the time course. The analgesic and relative immobility effects of O-2486 were still present at two hours but not sedation and hypothermia. It was anticipated this analog would have a somewhat longer duration of action because of the alpha methyl substitution which theoretically should retard hydrolysis. Indeed, this analog has a longer duration of action than O-2426. However, direct comparison is complicated by the fact that a much higher dose of O-2486 was required because it is less potent than O-2426. It does appear that there is some separation of pharmacological actions with O-2486 and not O-2426.

Figure 9. Time course of O-2485 or saline after i.v. administration. The ED₅₀'s of O-2485 after i.v. administration were 0.45, 1.0, 1.9 and 1.9 μ moles/kg in spontaneous activity, tail-flick, rectal temperature and relative immobility, respectively. The time course was carried out with a dose of 3 mg/kg (5 μ moles/kg). It is evident that the antinociceptive effect of this analog is retained even after recovery from sedation. At four hours, antinociception is present when almost all other effects have dissipated.

Figure 10. Time course of O-2545 or saline after i.v. administration. The ED₅₀'s of O-2545 were 0.09, 0.16, 0.29 and 0.14 μ moles/kg. Therefore, a dose of 0.24 μ moles/kg, i.v., was used for the time course. At 1 hr all effects, except ring immobility, are present but only antinociception is present at 2 hours.

Figure 11. Time course of O-2716 or vehicle (1:1:18 ethanol:emulphor:saline) after i.v. administration. The ED₅₀'s of O-2716 after i.v. administration were 0.3, 0.9, 0.15 and 0.20 μ moles/kg for spontaneous activity, tail-flick, rectal temperature and relative immobility, respectively. Therefore, a dose of 0.1 mg/kg (0.24 μ moles/kg) was used for the time course. This analog was relatively short acting with most of the effects gone by 1 hour and no separation of effects.

Figure 12. Time course of O-2715 or vehicle (1:1:18 ethanol:emulphor:saline) after i.v. administration. The ED₅₀'s of O-2715 after i.v. administration were 0.004, 0.06, 0.14 and 0.07 μ moles/kg in spontaneous activity, tail-flick, rectal temperature, and relative

immobility, respectively. A dose of 0.3 mg/kg (0.74 μ moles/kg) was chosen for the time course. The duration of antinociception and hypothermia exceeded that of sedation and relative immobility.

Figure 13. Potency of O-2426 following oral administration 30 minutes before the start of testing. The results demonstrate that this analog is effective in all four tests at a dose of 1 mg/kg.

Figure 14. Potency of O-2486 after oral administration 30 minutes before the start of testing. The results show that a dose of 10 mg/kg is highly effective in all four pharmacological measures.

Figure 15. Potency of O-2485 after oral administration 30 minutes before the start of testing. This analog is active in all measures following an oral dose of 10 mg/kg.

Figure 16. Potency of O-2545 following oral administration 30 minutes before the start of testing. A dose of 10 mg/kg was fully effective in producing antinociception, hypothermia and ring immobility but was only a partial agonist in producing sedation.

Figure 17. Time course of O-2545 or vehicle (1:1:18 ethanol:emulphor:saline) following oral administration at different time points before testing. A dose of 10 mg/kg was used and was found to produce the full range of effects up to 2 hours.

Figure 18. Potency of O-2715 following oral administration 30 minutes before the start of testing. A dose of 10 mg/kg was active in all tests.

Figure 19. Time course of O-2715 (10 mg/kg) or vehicle (1:1:18 ethanol:emulphor:saline) following oral administration at different time points before testing. This dose produced effects that lasted only 1 hour.

Figure 20. Potency of O-2716 following oral administration 30 minutes before the start of testing. The maximum dose tested, 10 mg/kg, failed to produce complete antinociception.

Figure 21. Time course of O-2716 (10 mg/kg) or vehicle (1:1:18 ethanol:emulphor:saline) following oral administration at different time points before testing. The effects lasted at least 2 hours.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

The invention provides water-soluble cannabinoid analogs with high CB₁ and CB₂ receptor affinity and high bioavailability. Production of the compounds was based on two approaches to modification of tetrahydrocannabinol: structural alterations in 1) the alkyl side chains; and 2) at the phenolic hydroxyl group. The resulting series of analogs are soluble and/or miscible in water, show high bioavailability, and exhibit high affinity for the CB₁ and CB₂ receptors (i.e. they are cannabinoid agonists.)

By "water-soluble" we mean that 1mg of material in 1 ml of water gives a clear solution and is water miscible.

By "high affinity" we mean that the compounds exhibit a K_i in the range of about 0.03 nM to about 80nM, and preferably from about 0.03 nM to about 50 nM, for either the CB₁ or CB₂ receptors, or both.

In one embodiment of the invention, the structure of the water-soluble cannabinoid analog is as depicted in Formula 1:




Formula 1

In this structure R₁ may be H, or a C1-C6 lower alkyl group and may be straight-chained, branched or cyclic (e.g. CH₃). R₂ may be a 5-7 membered heterocyclic ring in which at least one of the member atoms is N. Examples of suitable 5-7 membered heterocyclic rings include but are not limited to piperidine, methyl piperidine, methyl piperazine, morpholine, etc. Alternatively, R₂ may be NR₃ where R₃ is H₂, H₃⁺, or mono or dialkyl C₁-C₆ (e.g. (CH₃)₂, CH(CH₃)₂, C(CH₃)₃, etc).

The invention further comprehends salts of the compounds depicted in Formula 1. Examples of suitable types of salts include but are not limited to HCl, iodine, ammonia, sulfates, tartrates, succinates, quaternary salts, etc. Those of skill in the art will recognize that any salts of the compounds may be used, so long as the salt retains water solubility.

5 In another aspect of the invention, a cannabinoid analog with a structure as presented in structural Formula 2 is provided.




Formula 2

In compounds of Formula 2, R₄ is a heterocyclic ring such as an azole or morpholine ring, examples of which include but are not limited to imidazole, 1H-imidazole, methyl
10 imidazole, pyrazole, triazole, and the like .

In addition, the compound may be provided as a salt (e.g. HCl, iodine, ammonia, sulfates, tartrates, succinates, quaternary salts, etc.). Those of skill in the art will recognize that any salts of the compounds may be used, so long as the salt retains water solubility.

15 In a preferred embodiment, the cannabinoid analog of Formula 2 is a water-soluble salt, and the heterocyclic ring is an imidazole ring (such as 1H-imidazole, methyl imidazole, etc.) or a morpholine ring.


In yet another aspect of the invention, cannabinoid analogs with the structure depicted in Formula 3 (and their salts, e.g. HCl, iodine, ammonia, sulfates, tartrates, succinates, quaternary salts, etc.) are provided. Those of skill in the art will recognize that
20 any salts of the compounds may be used, so long as the salt retains water solubility.



Formula 3

In compounds of Formula 3, R_5 may be, for example, NH_2 , $NHCH_3$, or NHR_6 , where R_6 is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N. Suitable examples of such heterocyclic rings include but are not limited to morpholine, homo-piperidine, pyrrolidine, piperidine, etc. Alternatively, R_5 may be a 5-7 membered heterocyclic ring in which at least one of the member atoms is N, suitable examples of which include but are not limited to morpholine, piperidine, piperazine, pyrrolidine, homo-piperidine, etc.

In yet another embodiment, the invention provides water-soluble cannabinoid analogs with the structure depicted in Formula 4 and their water soluble salts (e.g. HCl, iodine, ammonia, sulfates, tartrates, succinates, quaternary salts, etc.).




Formula 4

In Formula 4, R_7 may be H, or a C1-C6 lower alkyl group and may be straight-chained, branched or cyclic (e.g. CH_3). R_8 may be a 5-7 membered heterocyclic ring in which

at least one of the member atoms is N. Examples of suitable 5-7 membered heterocyclic rings include but are not limited to piperidine, methyl piperidine, methyl piperazine, morpholine, etc. Alternatively, R_8 may be NR_3 where R_3 is H_2 , H_3^+ , or mono or dialkyl C_1-C_6 (e.g. $(CH_3)_2$, $CH(CH_3)_2$, $C(CH_3)_3$, etc).

5 In compounds of Formula 4, R_9 may be, for example, NH_2 , $NHCH_3$, or NHR_6 , where R_6 is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N. Suitable examples of such heterocyclic rings include but are not limited to morpholine, homo-piperidine, pyrrolidine, piperidine, etc. Alternatively, R_9 may be a 5-7 membered heterocyclic ring in which at least one of the member atoms is N, suitable examples of which
 10 include but are not limited to morpholine, piperidine, piperazine, pyrrolidine, homo-piperidine, etc.


In one embodiment of the invention, the compound of Formula 4 is as depicted in Formula 5.



Formula 5


15

In addition, the invention provides a cannabinoid analog with general Formula 6



Formula 6

In compounds of Formula 6, $R_1 = H$, $-COCHR_3-CH_2-CH_2-R_4$; $R_2 = CN$ or COR_7 ; $R_3 = H$, straight-chained, branched or cyclic C_1-C_6 lower alkyl. In the formula, R_4 and R_7 may be the same or different and are: NH_2 , $NHCH_3$, $N(R_8)_2$, where $R_8 = COR_7$; or a 5-7 membered heterocyclic ring with at least one N atom; or NHR_5 , where R_5 is a 5-7 membered heterocyclic ring with one N atom. In one embodiment of the invention, the 5-7 membered heterocyclic ring is



The compounds of the present invention are useful for a variety of therapeutic applications. For example, the compounds are useful for treating or alleviating symptoms of diseases and disorders involving CB_1 and CB_2 receptors, including appetite loss, nausea and vomiting, pain, multiple sclerosis and epilepsy. For example, they may be used to treat pain (i.e. as analgesics) in a variety of applications including but not limited to pain management. By "treating" we mean that the compound is administered in order to alleviate symptoms of the disease or disorder being treated. Those of skill in the art will recognize that the symptoms of the disease or disorder that is treated may be completely eliminated, or may simply be lessened. Further, the compounds may be administered in combination with other drugs or treatment modalities.

It is well documented that agents that activate CB_1 cannabinoid receptors stimulate appetite, nausea and vomiting, and pain (Martin B.R. and Wiley, J.L, Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis and pain, *Journal of Supportive Oncology* 2: 1-10, 2004), multiple sclerosis (Pertwee, R.G., Cannabinoids and multiple sclerosis, *Pharmacol. Ther.* 95, 165-174, 2002) and epilepsy (Wallace, M.J., Blair, R.E., Falenski, K.WW., Martin, B.R., and DeLorenzo, R.J. *Journal Pharmacology and Experimental Therapeutics*, 307: 129-137, 2003). In addition, CB_2 receptor agonists have been shown to be effective in treating pain (Clayton N., Marshall F.H., Bountra C., O'Shaughnessy C.T., 2002. CB_1 and CB_2 cannabinoid receptors are implicated in inflammatory pain. 96, 253-260; Malan T.P., Ibrahim M.M., Vanderah T.W., Makriyannis A., Porreca F., 2002. Inhibition of pain responses by activation of $CB(2)$ cannabinoid

receptors. *Chemistry and Physics of Lipids* 121, 191-200; Malan T.P., Jr., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., Makriyannis A., 2001. CB2 cannabinoid receptor-mediated peripheral antinociception. 93, 239-245.; Quartilho A., Mata H.P., Ibrahim M.M., Vanderah T.W., Porreca F., Makriyannis A., Malan T.P., Jr., 2003. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. *Anesthesiology* 99, 955-960) and multiple sclerosis (Pertwee, R.G., Cannabinoids and multiple sclerosis, *Pharmacol. Ther.* 95, 165-174, 2002) in animal models. The compounds described herein have high affinity for both CB₁ and CB₂ receptors and produce cannabinoid *in vivo* effects. These compounds are also effective analgesics in the radiant heat model of pain as measured by the tail-flick response (see Examples).

Implementation will generally involve identifying patients suffering from the indicated disorders and administering the compounds of the present invention in an acceptable form by an appropriate route. The exact dosage to be administered may vary depending on the age, gender, weight and overall health status of the individual patient, as well as the precise etiology of the disease. However, in general for administration in mammals (e.g. humans), dosages in the range of from about 0.1 to about 30 mg of compound per kg of body weight per 24 hr., and more preferably about 0.1 to about 10 mg of compound per kg of body weight per 24 hr., are effective.

Administration may be oral or parenteral, including intravenously, intramuscularly, subcutaneously, intradermal injection, intraperitoneal injection, etc., or by other routes (e.g. transdermal, sublingual, oral, rectal and buccal delivery, inhalation of an aerosol, etc.). In a preferred embodiment of the invention, the water-soluble cannabinoid analogs are provided orally or intravenously.

In particular, the phenolic esters of the invention (Formula 1) are preferentially administered systemically in order to afford an opportunity for metabolic activation via *in vivo* cleavage of the ester. In addition, the water soluble compounds with azole moieties at the pentyl side chain (Formula 2, e.g. with imidazole moieties) do not require *in vivo* activation and may be suitable for direct administration (e.g. site specific injection).

The compounds may be administered in the pure form or in a pharmaceutically acceptable formulation including suitable elixirs, binders, and the like (generally referred to as "carriers") or as pharmaceutically acceptable salts (e.g. alkali metal salts such as sodium,

potassium, calcium or lithium salts, ammonium, etc.) or other complexes. It should be understood that the pharmaceutically acceptable formulations include liquid and solid materials conventionally utilized to prepare both injectable dosage forms and solid dosage forms such as tablets and capsules and aerosolized dosage forms. In addition, the compounds may be formulated with aqueous or oil based vehicles. Water may be used as the carrier for the preparation of compositions (e.g. injectable compositions), which may also include conventional buffers and agents to render the composition isotonic. Other potential additives and other materials (preferably those which are generally regarded as safe [GRAS]) include: colorants; flavorings; surfactants (TWEEN, oleic acid, etc.); solvents, stabilizers, elixirs, and binders or encapsulants (lactose, liposomes, etc). Solid diluents and excipients include lactose, starch, conventional disintegrating agents, coatings and the like. Preservatives such as methyl paraben or benzalkonium chloride may also be used. Depending on the formulation, it is expected that the active composition will consist of about 1% to about 99% of the composition and the vehicular "carrier" will constitute about 1% to about 99% of the composition. The pharmaceutical compositions of the present invention may include any suitable pharmaceutically acceptable additives or adjuncts to the extent that they do not hinder or interfere with the therapeutic effect of the active compound.

The administration of the compounds of the present invention may be intermittent, bolus dose, or at a gradual or continuous, constant or controlled rate to a patient. In addition, the time of day and the number of times per day that the pharmaceutical formulation is administered may vary and are best determined by a skilled practitioner such as a physician. Further, the effective dose can vary depending upon factors such as the mode of delivery, gender, age, and other conditions of the patient, as well as the extent or progression of the disease. The compounds may be provided alone, in a mixture containing two or more of the compounds, or in combination with other medications or treatment modalities. The compounds may also be added to blood *ex vivo* and then be provided to the patient.

The cannabinoid analogs of the invention are also valuable as research tools, e.g. for investigational purposes.

EXAMPLES

EXAMPLE 1.

Nonstandard abbreviations: Δ^9 -THC, Δ^9 -tetrahydrocannabinol; %MPE, percent maximum possible effect; CB, cannabinoid receptor; CP55940, (-)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol.

Introduction

Presently, there are numerous structural classes of cannabinoid receptor agonists, all of which require solubilization for experimental purposes because of their water-insolubility. One strategy for solubilizing water-soluble tetrahydrocannabinols is conversion of the phenolic hydroxyl to a morpholinobutyryloxy substituent. The hydrochloride salts of these analogs are water-soluble and active *in vivo* when administered in saline. The present investigation demonstrates that an array of hydrochloride salts of substituted butyryloxy esters are water-soluble and highly potent. The substitutions include piperidine, piperazine, and alkyl substituted amino moieties. It was also discovered that incorporation of a nitrogenous moiety in the alkyl side chain of tetrahydrocannabinol increased pharmacological potency. A series of carboxamido analogs exhibited high pharmacological potency but their hydrochloride salts were not water-soluble. On the other hand, incorporation of imidazoles in the terminus of the side chain led to water-soluble hydrochloride salts that were highly potent when administered in saline to laboratory animals. It is now possible to conduct cannabinoid research with agonists that are water-soluble and thus obviating the need of solubilizing agents.

An objective of the investigations noted below was to explore possible structural alterations in the THC structure that would render it water-soluble. An additional objective was to develop a series of water-soluble analogs that were not prodrugs.

Materials and Methods. Male ICR mice (Harlan Laboratories, Indianapolis, IN) weighing between 24 to 30 g were used in all experiments. Mice were maintained on a 14:10-hr light/dark cycle with food and water available *ad lib*. All test groups consisted of 6 to 12 mice. THC was obtained from NIDA and dissolved in a vehicle consisting of ethanol, emulphor and saline in a ratio of 1:1:18. Analogs were dissolved either in the vehicle or saline depending upon their water solubility. All chemicals were purchased from Sigma (St. Louis, MO) except the following: [35 S]GTP γ S (1250 Ci/mmol) was purchased from New

England Nuclear Group (Boston, MA), GTP γ S from Boehringer Mannheim (New York, NY), Dulbecco's modified Eagle's medium (DMEM) from GIBCO BRL (Grand Island, NY), Whatman GF/B glass fiber filters from Fischer Scientific (Pittsburg, PA), fetal calf serum (FCS) and fetal bovine serum (FBS) from HyClone Laboratories (Logan, UT) and Budget-Solve scintillation fluid from RPI Corp. (Mount Prospect, Ill).

Synthesis of compounds. All compounds were synthesized from various intermediates **2a-c** prepared using our published procedure (Singer et al., 1998) and as shown in Schemes 2-7 of Figures 1-6, starting with the commercially available 5-cyano-dimethoxyresorcinol **1** (Scheme 1, Figure 1). Compounds listed in **Table 1a-c** were synthesized from the acid **7** using standard procedures for the preparation of amides. The reverse amides (O-2589, O-2590, O-2619 and O-2620) were synthesized from **5** by conversion to the amine via the azide, followed by condensation with the appropriate acids using either the acid chloride or the carbodiimide (EDCI/DMAP) procedures. All the N-alkylated compounds listed in **Table 2a-c** were synthesized from **5** by protection of the phenol as the TBDMS derivative, which was treated with the appropriate amine in the presence of NaH/DMF, to give the target compounds. The C-alkylated imidazole derivative (O-2737) was synthesized from **7** by conversion of the acid group to the aldehyde, followed by condensation with glyoxal/NH₃ to form the 2-imidazole derivative (Dhanak et al., 2001). The phenolic esters listed in **Table 3a-c** were synthesized from **6** using a published procedure (Razdan et al., 1976). The various acids used in their preparation were prepared according to literature procedures (Blicke et al., 1941; Cruickshank and Sheehan, 1961; Razdan et al., 1976). The quarternary compounds were synthesized by the treatment of the amines with CH₃I in ether. The compound listed in **Table 4** was synthesized from the amide O-2372 (see Table 1a) and diisopropylaminobutyric acid.HCl using the EDCI/DMAP procedure and the free base thus obtained was converted to its hydrochloride. All compounds showed appropriate ¹H NMR profiles (Jeol Eclipse 300 MHz; Jeol USA, Inc., Peabody, MA) and were characterized on the basis of their ¹H NMR profiles, TLC, and elemental analyses. Detailed synthesis Schemes 1-6 for the compounds are given in Figures 1-6, respectively.

For Tables 1-4, CB₁ and CB₂ receptor binding was carried out in CHO (Chinese hamster ovary) and HEK (human embryonic kidney) cells, respectively, with the exception of the THC and CP 55,940 CB₁ binding, which were performed in rat brain membranes.

GTP γ S binding was carried out in CHO cells and maximal binding was expressed as a percentage of stimulation produced by CP 55,940. For the *in vivo* studies, the drugs were dissolved in either saline or emulphor:ethanol:saline (E:E:S) as indicated. The ED50 values are provided as μ moles/kg for reducing spontaneous activity (S.A), producing antinociception in the tail-flick procedure (T.F., lowering rectal temperature (R.T.) And producing relative immobility (R.I.) In mice. Solubility was determined by dissolving 1 mg of analog in 1 ml of water and by visual observation. "N.D." means "not determined". The results are presented graphically in Figures 7 through 21.













Table 1A. Carboxamido Pentyl Side Chain Analogs

O#	Name	Structure or R group
	Δ^9 -THC	
	CP 55,940	
O-2352	Carboxamido	-CONH ₂
O-2490	N-(Methyl)carboxamido	-CONHCH ₃

O-2544	N-(Morpholin-1-yl)-carboxamido	
O-2489	N-(Homo-piperidin-1-yl)-carboxamido	
O-2543	N-(Pyrrolidin-yl)-carboxamido	
O-2372	Morpholino-carboxamido	
O-2373	Piperidino-carboxamido	
O-2381	Methylepiperazino-carboxamido	
O-2399	Pyrrolidino-carboxamido	
O-2421	Homopiperidino-carboxamido	
O-2589	2,4-Dimethyl-thiazole-5-carboxamide	




O-2590	5-Methyl-2-phenyl-oxazol-4-yl-acetamide	
O-2619	Morpholino-1-carboxylic acid amide	
O-2620	Di(morpholino-1-carboxylic acid) amide	


Table 1B. Carboxamido Pentyl Side Chain Analogs

O# or Name	CB ₁ Ki	CB ₂ Ki	CB ₁ EC50	CB ₁ %CP Stim
Δ ⁹ -THC	41.0	49.1±5.11		
CP 55,940	0.9±0.2			200
O-2352	13.1±0.61	0.84±0.05	42 ±4.0	95 ±0.30
O-2490	18.7 ±0.58	3.16 ±0.75	64.2 ±10.6	92.7 ±7.81
O-2544	5.97 ±0.65	11.4 ±0.91	39.7 ±11.4	116 ±3.71
O-2489	15.8 ±0.44	35.3 ±4.48	86.6 ±17.4	112 ±2.32
O-2543	23.3 ±3.40	10.8 ±0.08	81.13 ±40.02	71.3 ±4.23
O-2372	1.30 ±0.12	0.57 ±0.04	5.88 ±0.42	120 ±1.11
O-2373	0.96 ±0.11	0.96 ±0.01	13.5 ±1.81	119 ±2.05
O-2381	112 ±14	389 ±46	ND	ND

O-2399	2.85 ±0.52	2.86 ±0.68	275 ±87.9	117 ±4.90
O-2421	4.24 ±1.01	3.45 ±0.58	23.2 ±2.06	81.8 ±8.96
O-2589	244 ±28.5	38.4 ±7.62	ND	ND
O-2590	890 ±161	169 ±39.1	ND	ND
O-2619	18.6 ±3.94	2.26 ±0.38	86 ±3.10	116 ±7.94
O-2620	3020 ±579	772 ±60.5	ND	ND

Table 1C. Carboxamido Pentyl Side Chain Analogs

O# or Name	S. A. (μmole/kg)	T.F. (μmole/kg)	R.T. (μmole/kg)	R.I (μmole/kg)	Solubility	Clogp
Δ ⁹ -THC	2.23	2.77	2.23		No	7.238
CP 55,940	0.11	2.77	0.93	0.92	No	5.819
O-2352	0.16	0.84	1.72	0.93	No	5.699
O-2490	0.49	1.37	>1	>1	No	5.735
O-2544	0.17	0.48	0.25	0.63	No	5.869
O-2489	2.07	2.53	8.50	20.49	No	7.153
O-2543	0.71	0.75	8.19	25.83	No	6.035
O-2372	0.01	0.01	0.07	0.03	No	6.000
O-2373	0.02	0.03	0.03	0.04	No	6.794
O-2381	21.43	34.03	51.05	182.56	No	6.561
O-2399	0.03	0.10	0.23	0.15	No	6.235
O-2421	0.15	0.16	0.44	0.86	No	7.353
O-2589	ND	ND	ND	ND	No	7.437
O-2590	ND	ND	ND	ND	No	7.499
O-2619	ND	ND	ND	ND	No	6.160
O-2620	ND	ND	ND	ND	ND	7.925

Table 2a. Imidazole, Pyrazole, and Triazole Pentyl Side Chain Analogs

O#	Name	R
	Δ^9 -THC	
	CP 55,940	
O-2545	Imidazol-1-yl	
O-2545	Imidazol-1-yl	
O-2651	2-Methyl-imidazol-1-yl	
O-2715	Pyrazol-1-yl	
O-2716	1,2,4-Triazol-1-yl	



O-2737	1H-Imidazol-2-yl	 ·HCl
O-2737	1H-Imidazol-2-yl	 ·HCl

Table 2b. Imidazole, Pyroazole, and Triazole Pantyl Side Chain Analogs

O# or Name	CB ₁ Ki (nM)	CB ₂ Ki (nM)	CB ₁ EC(50)	CB ₁ %CP Stim	Vehicle
Δ ⁹ -THC	41.0	49.1±5.11			
CP 55,940	0.9±0.2			100	
O-2545	1.34±0.17	0.12±0.003	29.3±3.27	107±6.19	E:E:S
O-2545	1.47±0.22	0.32±0.02	4.57±0.72	84±5.01	Saline
O-2651	13.9±0.83	1.22±0.28	82.9±45.7	33.4±3.41	Saline
O-2715	1.94±0.29	1.52±0.31	4.03±0.28	93.0±1.75	E:E:S
O-2716	3.43±0.16	0.92±0.07	36.8±4.23	93.1±1.65	E:E:S
O-2737	54.0±4.91	14.8±1.14	ND	ND	Saline
O-2737	54.9±4.91	14.8±1.14	ND	ND	E:E:S

Table 2c. Imidazole, Pyroazole, and Triazole Pantyl Side Chain Analogs

O# or Name	S.A (μmole/kg)	T.F. (μmole/kg)	R.T. (μmole/kg)	R.I. (μmole/kg)	Solubility	Clogp
Δ ⁹ -THC	2.23	2.77	2.23			7.238
CP 55,940	0.11	2.77	0.93	0.92		5.819
O-2545	0.01	0.07	0.04	0.13	No	5.860
O-2545	0.09	0.16	0.29	0.14	Yes	5.860

O-2651	1.46	1.75	3.58	4.29	Yes	7.069
O-2715	0.004	0.06	0.14	0.07	No	7.070
O-2716	0.03	0.09	0.15	0.20	No	6.070
O-2737	>2.2	>2.2	>2.2	>2.2	Yes	6.646
O-2737	>10	>10	>10	>10	Yes	6.646




Table 3a. Pharmacological Activity of Phenolic Esters

O#	Name	R
	Δ^9 -THC	
	CP 55,940	
O-1057	morpholinobutyryloxy	•HCl
O-2365	1-(4-N-piperidinobutyryloxy)	•HCl
O-2374	1-(2-methyl-4-N-piperidinobutyryloxy)	•HCl
O-2426	1-(4-N-2-methylpiperidinobutyryloxy)	•HCl










O-2486	1-2-methyl-(4-N-2'-methylpiperidino-butryloxy)	 ·HCl
O-2383	1-(4-N(4'-methylpiperazino)butryloxy	 ·2 HCl
O-2427	1-2-methyl-4-N(4'-methyl-piperazino)butryloxy	 ·2 HCl
O-2484	1-(4-N,N-dimethylaminobutryloxy)	 ·HCl
O-2487	1-(2-methyl-4,N,N-dimethylaminobutryloxy)	 ·HCl
O-2548	1-(4-N,N,N-trimethylammoniumbutryloxy)	 I ⁻
O-2650	1-(2-methyl-4-N,N,N-trimethylammoniumbutryloxy	 I ⁻
O-2382	1-(4-N,N-diisopropylaminobutryloxy)	 ·HCl
O-2485	1-(2-methyl-4-N,N-diisopropylaminobutryloxy)	 ·HCl

Table 3b. Pharmacological Activity of Phenolic Esters

O# or Name	CB ₁ Ki (nM)	CB ₂ Ki (nM)	CB ₁ EC(50)	CB ₁ %CP Stim	Vehicle
Δ ⁹ -THC	41.0	49.1±5.11			
CP 55,940	0.9±0.2			100	
O-1057	15.3±5	ND	ND	ND	E:E:S
O-2365	2.73±0.83	0.20±0.07	8.43±2.32	93±0.68	Saline
O-2374	4.62±2.20	1.10±0.10	16.5±6.97	80.9±3.73	Saline
O-2426	2.63±0.55	0.70±0.09	22.1±7.79	77.0±5.87	Saline
O-2486	11.3±1.40	0.34±0.04	36.8±5.98	81.3±17.9	Saline
O-2383	2.01±0.14	0.78±0.13	15.9±3.11	82.0±5.84	Saline
O-2427	6.71±1.80	1.56±0.47	15.6±7.76	97.9±10.4	Saline
O-2484	2.61±0.83	0.23±0.03	16.9±1.74	126±11.3	Saline
O-2487	5.89±0.79	0.44±0.07	16.1±6.03	119±12.2	E:E:S
O-2548	14.7±4.00	0.35±0.03	60.2±13.2	112±1.18	E:E:S
O-2650	45.4±3.79	7.4±0.24	138±35.8	113±4.65	Saline
O-2382	5.59±1.90	1.98±0.08	17.9±1.03	77.6±5.58	Saline
O-2485	81.7±11.3	1.99±0.24	ND	ND	Saline

Table 3c. Pharmacological Activity of Phenolic Esters

O# or Name	S.A (μmole/kg)	T.F. (μmole/kg)	R.T. (μmole/kg)	R.I. (μmole/kg)	Soluble	Clogp
Δ ⁹ -THC	2.23	2.77	2.23			7.238
CP 55,940	0.11	0.23	0.93	0.92		5.819
O-1057	0.03	0.03	0.10		Yes	6.934
O-2365	0.02	0.07	0.03	0.10	Yes	6.419
O-2374	0.18	0.41	0.72	0.57	Yes	8.457
O-2426	0.05	0.04	0.10	0.11	Yes	8.523
O-2486	0.07	0.33	2.76	0.94	Yes	8.832

O-2383	0.03	0.04	0.09	0.09	Yes	6.031
O-2427	0.23	0.17	0.40	0.22	Yes	6.314
O-2484	0.07	0.09	0.35	0.16	Yes	6.988
O-2487	0.40	0.26	0.40	0.59	Yes	7.207
O-2548	0.02	0.05	0.09	0.08	Yes	7.845
O-2650	0.0002	1.99	3.82	14.81	Yes	8.154
O-2382	0.04	0.05	0.85	0.06	Yes	8.989
O-2485	0.45	1.00	1.90	1.92	Yes	8.973




Table 4a. Diisopropylaminobutyrate of Δ^8 -THC-3-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)

O#	CB ₁ Ki (nM)	CB ₂ Ki (nM)	CB ₁ EC(50)	CB ₁ %CP Stim
O-2694	3.7±0.43	2.77±0.44	28.3±3.47	120±8.04

Table 4b. Diisopropylaminobutyrate of Δ^8 -THC-3-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl)

O#	S.A (μ mole/kg)	T.F. (μ mole/kg)	R.T. (μ mole/kg)	R.I. (μ mole/kg)	Clogp	Soluble
O-2694	0.045	0.035	0.12	0.11	8.245	Yes

cLogP calculations. Absolute solubility determinations were not performed. Rather, cLogP calculations were performed using the CS ChemDraw Ultra software (Cambridge Soft Corporation, Cambridge, MA).

Receptor Binding. HEK-293 cells stably expressing the human CB₁ receptor were cultured in DMEM with 10% FBS and Chinese Hamster Ovary (CHO) cells stably expressing the human CB₂ receptor were cultured in DMEM with 10% FCS. Cells were harvested by replacement of the media with cold phosphate-buffered saline containing 1 mM EDTA followed by centrifugation at 1000 x g for 5 min at 4°C. The pellet was resuspended in 50 mM Tris-HCl containing 320 mM sucrose, 2 mM EDTA and 5 mM MgCl₂ (pH 7.4) (centrifugation buffer), then centrifuged at 1000 x g for 10 min at 4°C, and the resulting supernatant was saved. This process was repeated twice. The supernatant fractions were combined and centrifuged at 40,000 x g for 30 min at 4°C. The resulting P2 pellet was resuspended in assay buffer (50 mM Tris-HCl (pH 7.4), 3 mM MgCl₂, 0.2 mM EGTA, and 100 mM NaCl) and protein was determined by the method of Bradford ENRfu (Bradford 1976). Membranes were stored at -80°C until use. Membrane homogenates (50 µg) were incubated with 0.5 nM [³H]CP55,940 in the presence of varying concentrations (1 nM-10 µM) of test compounds in assay buffer with BSA (5 mg/ml) in a 0.5 ml total volume. Non-specific binding was measured in the presence of 1 µM CP55,940. The assay was incubated at 30°C for 1 hr and terminated by addition of ice cold 50 mM Tris-HCl plus BSA (1 mg/ml) (pH 7.4) followed by filtration under vacuum through Whatman GF/B glass fiber filters with 3 washes with cold Tris buffer. Bound radioactivity was determined by liquid scintillation spectrophotometry at 50% efficiency after extraction by shaking samples for 30-60 min with Budget-Solve scintillation fluid. Data are reported as the mean ± SEM of three experiments, each performed in triplicate. K_i values were calculated from displacement data using EBDA (Equilibrium Binding Data Analysis; BIOSOFT, Milltown, NJ).

[³⁵S]GTPγS Binding Assays. Concentration-effect curves were generated by incubating membranes (10 µg prepared from CB₁ expressing cells as described above) in assay buffer containing BSA (1 mg/ml) with various concentrations of test compounds in the presence of 20 µM GDP and 0.1 nM [³⁵S]GTPγS in a 1 ml total volume. [³⁵S]GTPγS binding stimulated by 2 µM CP55,940 was used as an internal standard in each assay. Basal binding was assessed in the absence of agonist, and nonspecific binding was measured in the presence of

10 μ M GTP γ S. The reaction was incubated for 90 min at 30°C and terminated by filtration under vacuum through Whatman GF/B glass fiber filters with 3 washes with cold (4°C) Tris buffer (50 mM Tris-HCl, pH 7.4). Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency after extraction overnight in ScintiSafe Econo 1 scintillation fluid. Data are reported as mean $\pm$ SEM of three experiments, each performed in triplicate. Nonlinear regression analysis was conducted by iterative fitting using JMP (SAS for Macintosh). Net-stimulated [35 S]GTP γ S binding is defined as [35 S]GTP γ S binding in the presence of drug minus basal and percent stimulation is expressed as (net stimulated [35 S]GTP γ S binding/basal) x 100%.

10 **Behavioral Evaluations.** All animals were allowed to acclimate to the observation room overnight. Behavioral effects were assessed in the tetrad model in order to measure potency in producing antinociception, catalepsy, hypothermia, and hypomobility. The baselines for tail-flick latency (2-4 seconds) and rectal temperature were determined prior to i.v. injections. Baseline rectal temperatures were measured using a telethermometer and a thermometer probe inserted to 25 mm (Yellow Springs Instrument Co., Yellow Springs, OH). The mice were then given either an i.v. i.c.v. injection of the analog. The mice were placed in individual photocell activity chambers 5 min later. Spontaneous activity was monitored for 10 min in a Digiscan Animal Activity Monitor (Omnitech Electronics, Inc., Columbus, OH) as measured by the number of interruptions of 16 photocell beams per chamber. The total number of beam interruptions during the 10-min period was determined and presented as total counts. The mice were then assessed at 20 min following the i.v. injection for antinociception using the tail-flick reaction time to a heat stimulus. A 10-sec maximum latency was used in order to avoid tail injury. The results are presented as % MPE and are calculated as follows:

$$\%MPE = [(test\ latency - control\ latency) / (10\ sec - control\ latency)] \times 100$$

Rectal temperature was measured 30 min after the i.v. injection. The change in rectal temperature (Δ° C) following analog administration was calculated for each animal. Relative immobility (catalepsy) was measured 40 min after the i.v. injection by the ring-immobility test. Mice were placed on a ring 5.5 cm in diameter attached to a stand at a height of 16 cm. The amount of time the mice spent motionless on the ring during the 5-minute procedure was measured, with the criteria of immobility being defined as the absence of all voluntary

movements, including whisker movement, but excluding respiration. The percent immobility was calculated as: % immobility = [time immobile (sec)]/[length of session (sec)] x 100. Mice that fell from the ring or actively jumped were allowed five attempts. After the fifth escape these mice were removed from the ring and not included in the calculations.

5 Data was collected from 6-12 mice for each condition tested.

All studies were carried out in accordance with the Declaration of Helsinki and Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health.

Data analysis. Maximal possible effects (100%) served as estimates for the maximal effects for effects on spontaneous activity and tail-flick response. For catalepsy, a maximal possible effect was considered to be 60%, and -6 °C was used as maximal change in rectal temperature based upon data from numerous previous studies with classical cannabinoid compounds (Martin et al., 1991; Compton et al., 1993). ED₅₀ was defined as the dose at which half maximal effect occurred. For compounds that were active in one or more test, ED₅₀s were calculated separately using least-squares linear regression on the linear part of the dose-effect curve for each measure in the mouse tetrad, plotted against log₁₀ transformation of the dose.

Results

Carboxamido Pentyl Side Chain Analogs. There is ample evidence that a wide range of structural alterations at the terminal carbon of a dimethylpentyl chain can be made without diminishing pharmacological activity. For example, addition of a cyano moiety at this position greatly enhances CB₁ receptor affinity and pharmacological potency (Martin et al., 1999). Therefore, a series of carboxamido derivatives were prepared as shown in Table 1. Most of the analogs exhibited high affinity for both CB₁ and CB₂ receptors, were effective in stimulating [³⁵S]GTPγS binding and produced *in vivo* cannabinoid effects. The unsubstituted carboxamido (O-2352) exhibited excellent CB₁ receptor affinity and even higher CB₂ receptor affinity. Agonist-stimulated [³⁵S]GTPγS binding indicated it was a potent and fully efficacious agonist. In the *in vivo* mouse model, it was slightly more potent than Δ⁹-THC following i.v. administration. Moreover, its lipophilicity was calculated to be 35-fold less than of Δ⁹-THC. CB₁ receptor affinity, efficacy ([³⁵S]GTPγS binding) and pharmacological potency were retained with carboxamido substitutions containing methyl

(O-2490), morpholinyl (O-2544), homo-piperidinyl (O-2489) or pyrrolidinyl (O-2543) moieties, although there were several notable differences between these compounds. The CB2 receptor selectivity was greatly diminished with all substitutions and was actually reversed with the morpholino (O-2372) and piperidino (O-2373) analogs. Interestingly, the homo-piperidinyl (O-2489) and pyrrolidinyl (O-2543) analogs were 4-25 fold less potent in producing hypothermia and catalepsy than in producing hypoactivity and analgesia. In addition, O-2490 failed to produce maximal effects in hypothermia and catalepsy assays at a dose (1 mg/kg) that produced maximal effects in the other two measures. A separation in pharmacological potencies of this magnitude is unusual. The calculated lipophilicity was similar for all of the aryl hydrazines with the exception of the homo-piperidinyl (O-2489) analog that was found to be 28 times more lipid soluble than the unsubstituted carboxamido analog (O-2352).

Five carboxamido analogs were prepared with the morpholino (O-2372), piperidino (O-2373), pyrrolidino (O-2399), and homo-piperidino (O-2421) having high CB₁ and CB₂ receptor affinity, high efficacy in [³⁵S]GTPγS binding, and very high *in vivo* potency in all four pharmacological measures. The most active compounds (O-2372 and O-2373) were 100-200 times more potent than Δ⁹-THC after i.v. administration. It is noteworthy that a simple change from a piperidine to a piperazine (O-2381) decreased CB₁ receptor affinity and pharmacological potency more than a hundred fold. Most of these compounds were slightly less lipophilic than Δ⁹-THC. Of the remaining compounds in Table 1, only O-2619 demonstrated reasonable affinity for the CB₁ receptor; however, it was not evaluated *in vivo*.

Compounds O-2352, O-2372, O-2373, O-2399, and O-2544 were converted to hydrochloride salts as confirmed by NMR. However, none of the HCl salts was water-soluble. These analogs were deemed representative of the analogs in Table 1, and therefore no attempts were made to convert the other analogs in this table to HCl salts. Due to lack of water-solubility, all of the analogs in Table 1 were administered to mice using the 1:1:18 vehicle. Imidazol-, Pyrazol-, and Triazol-pentyl Side Chain Analogs. The imidazol substitution (O-2545) on the terminal carbon atom of the side chain resulted in a high affinity CB₁ agonist that was fully efficacious in stimulating [³⁵S]GTPγS binding (Table 2). It exhibited even higher affinity for the CB₂ receptor. The free base of this analog, dissolved in 1:1:18 vehicle, produced the full spectrum of pharmacological effects in the mouse model

and proved to be at least 40-fold more potent than Δ^9 -THC in all measures. The hydrochloride salt of O-2545 was dissolved in saline and when administered to mice produced effects that were equivalent to those of the free base. The calculated lipophilicity (clogP) of this analog was 20 times less than that of Δ^9 -THC. A single methyl substitution at the 2 position of the imidazole (O-2651) reduced affinity for both CB₁ and CB₂ receptors: however, it was still water soluble. This relatively minor structural alteration had a greater impact on efficacy in that it was only a partial CB₁ receptor agonist in stimulating [³⁵S]GTP γ S binding. When administered in saline to mice, it was at least 10-fold less potent than the corresponding hydrochloride salt of O-2545. Both pyrazole (O-2715) and triazole (O-2716) analogs had high CB₁ receptor affinity and fully efficacious in stimulating [³⁵S]GTP γ S binding. They were also very potent in producing cannabinoid effects in the tetrad model. However, neither of these analogs was water-soluble. Attempts were made to prepare hydrochloride salts, but the salts could not be isolated because both compounds are weak bases. Merely changing the attachment position from the nitrogen on the imidazole (O-2545) to the carbon 2 position on the imidazole ring (O-2737) dramatically reduced CB₁ and CB₂ receptor affinities. As expected based upon their CB₁ receptor affinity, they exhibited only weak *in vivo* pharmacological activity. Placement of a morphino group at the terminal carbon position resulted in O-3226 that had high affinity for both CB₁ and CB₂ receptors, was water-soluble, and when dissolved in saline was very potent when administered to mice.

Phenolic esters. The phenolic esters in Table 3 represent an extension of earlier work on the morpholinobutyryloxy derivative of Δ^8 -THC (O-1057). As with O-1057, most of these analogs were water soluble upon conversion to hydrochloride salts. Substituting the morpholino with a piperidino (O-2365) or methypiperidino groups (O-2426) slightly increased CB₁ receptor affinity over that of O-1057. Both analogs were effective in stimulating [³⁵S]GTP γ S binding and very potent in the mouse behavioral assays. A methyl group was added to the carbon 1 position in the butyryl moiety in an attempt to delay hydrolysis and to increase chemical stability. This addition produced only a slight reduction in CB₁ receptor affinity and pharmacological potency. The greatest difference was seen with lipophilicity which was increased almost 100-fold by the addition of the methyl group to O-2365 but not to O-2426. The N-4'-methylpiperazino analogs (O-2383 and O-2427)

exhibited properties similar to the piperidino (O-2365) and N-2'-methyl-4-piperidino (O-2374) analogs. A series of N-alkylaminobutyryloxy analogs (O-2484, O-2487, O-2548, O-2650, O-2382, and O-2485) was prepared. For the most part, all of these analogs had good CB₁ receptor affinity, stimulated [³⁵S]GTPγS binding, and were potent when administered to mice (Table 3). The 2-methyl analogs (O-2650 and O-2485) were somewhat less potent pharmacologically and had lower CB₁ receptor affinity. It is particularly noteworthy that the quaternary analog O-2548 is very potent pharmacologically. Of course, it also has high lipophilicity despite being a quaternary compound.

4-Diisopropylaminobutyrate of Δ⁸-THC-3-(1,1-dimethyl-6-morpholin-4-yl-6-oxo-hexyl).

The fact that the diisopropylaminobutyrate of Δ⁸-THC (O-2382 in Table 3) had high receptor affinity and was extremely potent *in vivo* provided an opportunity to convert one of the water insoluble carboxamido analogs in Table 1 to a water soluble cannabinoid. Therefore, the morpholinocarboxamido (O-2372) was chosen, because it also has high receptor affinity and excellent *in vivo* potency despite being water-insoluble. The resulting analog, O-2694, was found to be water-soluble, retained high CB₁ and CB₂ receptor affinity, and exhibited high potency and efficacy in stimulating [³⁵S]GTPγS binding (Table 4). It was also highly potent *in vivo* despite an almost 200-fold increase in lipophilicity as compared to O-2372. However, according to cLogP values, it is only five-fold less lipophilic than O-2382.

Influence of route of administration. The absorption of THC following oral administration is both poor and erratic. It is assumed that the high lipophilicity of THC contributes to some extent to its low absorption. Therefore, the time course of three analogs with varying cLogP values was examined following their oral administration in mice. O-2545 (24 times less lipophilic than Δ⁹-THC) was administered at a dose of 10 mg/kg and different groups of mice were tested at 0.5, 1, 2, 4 and 6 hrs. The time course was similar for all four behavioral measures. For example, maximal analgesia in the tail-flick procedure was obtained at 30 min and decreased to only 85±11 % (mean ±sem) at two hrs. By four hrs the effects had largely dissipated. O-2716 is 15 fold less lipophilic than Δ⁹-THC. Its oral administration at a dose of 10 mg/kg resulted in a time course very similar to that of O-2545. Maximal effects were observed at 30 min and only a slight decrease in activity was observed at 2 hrs. At four hrs, few differences were observed between vehicle- and O-2716-treated mice. The lipophilicities of O-2715 and Δ⁹THC are almost identical. As predicted, the oral

administration of O-2715 (10 mg/kg) produced negligible effects at one hr ($21 \pm 6\%$ analgesia), and the effects further declined over time.

In order to determine whether these analogs would be active when injected into a specific site, several analogs were dissolved in water and injected i.c.v. The effects of these compounds were compared to that of THC (dissolved in emulphor:ethanol:saline) and to the O-1057, the hydrochloride salt of morpholinobutyryloxy analog of 5'-cyano-THC. The results in Table 5 show that THC was active with similar potencies in all tests, with the exception of weak antinociceptive activity. The morpholinobutyryloxy analog O-1057 was also active in all behavioral tests, albeit with considerable differences in potency between tests. It was considerably more potent in lowering body temperature and producing catalepsy than in decreasing spontaneous activity and producing antinociception. The 1-(4-N(4'-methylpiperazino)-butyryloxy) analog O-2383 demonstrated potency similar to that of O-1057 with the exception of a low ability to reduce body temperature. The remaining three analogs were imidazole derivatives (side chain) that were also quite potent. Of these three compounds, O-2545 was the most potent. There were also some differences in potencies among the four tests for each analog. However, a consistent pattern did not emerge with all of the compounds, although they did appear to be somewhat less potent in producing antinociception in the tail-flick assay.

Discussion

Extensive structure activity relationship studies began almost immediately after the structure of THC was established (Gaoni and Mechoulam, 1964; Edery et al., 1971; Razdan, 1986). These initial studies firmly established the importance of three structural features of THC: the C9 position, phenolic hydroxyl group, and pentyl side chain. These regions of the molecule continue to be the focus of structural modifications of THC. Elimination or structural modification of the phenolic hydroxyl group renders THC inactive at the CB₁ receptor (Razdan, 1986). Recently, a series of desoxy-THC analogs were found to lack CB₁ receptor affinity but retained their ability to interact with CB₂ receptors (Huffman et al., 2002). The side chain can easily be manipulated to increase agonist potency or to reduce or eliminate agonist efficacy (Martin et al., 1999). In addition, the terminal carbon atom of the side chain can tolerate a wide range of substituents (Martin et al., 1999). Therefore, structural modifications at the phenolic hydroxyl and side chain represent logical sites for

expanding the structure-activity relationship of THC and for developing water-soluble ligands.

As we had previously shown (Zitko et al., 1972; Pertwee et al., 2000), the addition of a basic functional group through an ester linkage at the phenolic hydroxyl group provides a means for preparing hydrochloride salts that are water-soluble. It is now evident that hydrochloride salts can be readily prepared when the terminal group in the butyryloxy group is either morpholino, piperidino or piperazino moieties. Since a free phenolic group is essential for interaction with the CB₁ receptor, it would appear that all of the compounds are readily hydrolyzed, since they are highly potent when administered i.v. to mice. In an effort to retard hydrolysis, we incorporated a methyl group on the alpha carbon of several analogs. While we have no direct evidence of the degree of hydrolysis that occurs in the receptor binding assays, it is noteworthy that the CB₁ receptor affinity decreased with the methyl addition, whereas the CB₂ receptor was less affected. These observations are consistent with decreased hydrolysis since a free hydroxyl is essential for CB₁ but not CB₂ receptor binding. It is also evident that an alkyl substituted amino or ammonium group forms a hydrochloride salt that is in turn water-soluble. Alpha methylation in the butyryloxy group had mixed results on CB₁ and CB₂ binding. In the case of the ammoniumbutyryloxy analogs (O-2548 and O-2650, Table 3), binding was increased for both receptor subtypes. However, binding was increased only for the CB₁ receptor with the dimethylaminobutyryloxy (O-2484 and O-2487) and diisopropylaminobutyryloxy (O-2382 and O-2485) analogs. In the latter case, CB₁ receptor binding was increased 15 fold with the alpha methyl addition. There was also considerable diminution in the pharmacological potency of the methyl derivative, again suggestive of decreased hydrolysis.

The second strategy for developing water-soluble derivatives was incorporation of nitrogenous constituents in the side chain that could be converted to hydrochloride salts. Earlier studies had demonstrated that a wide range of small substituents (hydroxy, bromo, cyano, azido, acetamido, etc.) could be incorporated into the terminus of the side chain (ref). Importantly, these studies demonstrated that the nitrogen containing substituents increased CB₁ receptor affinity and pharmacological potency. Therefore, it was not unexpected that the carboxamido (O-2352) and N-methylcarboxamido (O-2490) analogs would have reasonable receptor affinity and be pharmacologically active. The finding that the

incorporation of morpholinyl, piperidinyl, homo-piperidinyl and pyrrolidinyl groups on the side chain terminus retains pharmacological activity indicates for the first time that the receptor pharmacophore readily accommodates bulky substituents at this position. Similar findings were observed in the carboxamido series having a morpholino, piperidino, homo-piperidino and a pyrrolidino group with the exception that these analogs exhibited higher receptor affinity and greater pharmacological potency than the corresponding -yl analogs. It is interesting to note that the homo-piperidinyl analog in the carboxamido series (O-2489, Table 1) is considerably less potent than the corresponding homo-piperidino analog (O-2421). In addition, the methylpiperazino (O-2381) was a very weak agonist. These two observations suggest that electrostatic influences are more important than steric effects at this position. On the other hand, the loss in activity of the di(morpholino-1-carboxylic acid)amide (O-2620) is highly likely to be due to steric hinderance. While most of the carboxamido analogs exhibited high affinity and excellent pharmacological potency, it was disappointing that none of the hydrochloride salts was water-soluble. This lack of water solubility is not surprising since it is known that, although the amides can form salts, they are less water-soluble than amine salts which have greater basicity.

In contrast to the carboxamido analogs, the imidazole analogs readily formed hydrochloride salts that were water-soluble, whereas the less basic pyrazole and triazole analogs formed hydrochloride salts which were water-insoluble. The fact that the imidazole-1-yl analog (O-2545, Table 3) had high receptor affinity, efficacy similar to CP 55, 940 in stimulating GTPgS binding and high potency in the mouse behavioral assays make it an ideal water-soluble cannabinoid agonist. It is also 24-fold less lipophilic than THC and does not require metabolic conversion to an active constituent. Moreover, it has excellent stability in buffer and plasma and microsomal enzymes as compared to most of the analogs. The pyrazole and triazole analogs also exhibited excellent receptor affinity and high potency *in vivo* but as stated above, the hydrochloride salts are not water soluble. The dramatic decrease in receptor affinity and pharmacological potency that occurred with the imidazole-2-yl analog (O-2737) demonstrates the importance of electrostatic influences at the side chain terminus.

The question arises as to whether incorporation of both a phenolic ester and a side chain carboxamide (O-2694, Table 4) would provide even greater water solubility. Clearly,

this analog retained high affinity and excellent in vivo potency.

In summary, there are numerous effective means of synthesizing water-soluble cannabinoids. The conversion of the phenolic hydroxyl group to an ester that is readily hydrolyzed *in vivo* is an effective strategy. However, these analogs may be best suited for systemic administration, in contrast to site specific injections, since metabolic activation is required. On the other hand, incorporation of nitrogen-containing rings at the terminal carbon atom of the side chain allows for the preparation of hydrochloride salts that are readily water-soluble. The advantage of these compounds is that they do not require metabolic activation. It is now possible to use these same synthetic strategies to develop water-soluble CB₁ and CB₂ selective agonist and antagonists. The necessity of using solubilizing agents to order to evaluate the pharmacological properties of an agent poses challenges to the investigator. It will be understood by those of skill in the art that there may be a pharmacological interaction between vehicle and test agent. More likely, the vehicle will influence the pharmacokinetics of the test substance that adds an additional challenge when comparing data generated from different labs that utilize various vehicles. Elimination of solubilizing agents as vehicle eliminates possible artifacts arising from these substances.

References

- Blicke FF, Wright WB, Jr. and Zienty MF (1941) The action of heat on γ -alkoxybutyryl chlorides. *J. Amer. Chem. Soc.* **63**:2488-2490.
- Compton DR and Martin BR (1990) Pharmacological evaluation of water soluble cannabinoids and related analogs. *Life Sci.* **46**:1575-1585.
- Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR and Martin BR (1993) Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. *J. Pharmacol. Exp. Ther.* **265**:218-226.
- Cruickshank PA and Sheehan JC (1961) Intramolecular assistance of decarboxylative acylation. *J. Amer. Chem. Soc.* **83**:2891-2895.
- Dhanak D, Christmann LT, Darcy MG, Keenan RM, Knight SD, Lee J, Ridgers LH, Sarau HM, Shah DH, White JR and Zhang L (2001) Discovery of potent and selective phenylalanine derived CCR2 antagonists. Part1. *Bioorg. Med. Chem. Lett.* **11**:1445-1450.
- Edery H, Grunfeld Y, Ben-Zvi Z and Mechoulam R (1971) Structural requirements for cannabinoid activity. *Ann. N.Y. Acad. Sci.* **191**:40-53.

ElSohly MA, Harland EC, Benigni DA and Waller CW (1984) Cannabinoids in glaucoma II: The effect of different cannabinoids on intraocular pressure of the rabbit. *Curr. Eye Res.* **3**:841-850.

Gaoni Y and Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. *J. Amer. Chem. Soc.* **86**:1646-1647.

Harris LS, Carchman RA and Martin BR (1978) Evidence for the existence of specific cannabinoid binding sites. *Life Sci.* **22**:1131-1138.

Huffman JW, Bushell SM, Miller JR, Wiley JL and Martin BR (2002) 1-Methoxy-, 1-deoxy-11-hydroxy- and 11-Hydroxy-1-methoxy-Delta(8)- tetrahydrocannabinols: new selective ligands for the CB(2) receptor. *Bioorg Med Chem* **10**:4119-4129.

Juntunen J, Huuskonen J, Laine K, Niemi R, Taipale H, Nevalainen T, Pate DW and Jarvinen T (2003a) Anandamide prodrugs. 1. Water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide. *Eur J Pharm Sci* **19**:37-43.

Juntunen J, Vepsäläinen J, Niemi R, Laine K and Jarvinen T (2003b) Synthesis, in vitro evaluation, and intraocular pressure effects of water-soluble prodrugs of endocannabinoid noladin ether. *J Med Chem* **46**:5083-5086.

Khanolkar AD, Palmer SL and Makriyannis A (2000) Molecular probes for the cannabinoid receptors. *Chem. Phys. Lipids* **108**:37-52.

Little PJ, Kaplan NC and Martin BR (1987) Pharmacological profile of Δ^9 -THC carbamate. *Alc. Drug Res.* **7**:517-523.

Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R and Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. *Pharmacol. Biochem. Behav.* **40**:471-478.

Martin BR, Jefferson R, Winckler R, Wiley JL, Huffman JW, Crocker PJ, Saha B and Razdan RK (1999) Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. *J. Pharmacol. Exp. Ther.* **290**:1065-1079.

Nye JS, Voglmaier S, Martenson RE and Snyder SH (1988) Myelin basic protein is an endogenous inhibitor of the high-affinity cannabinoid binding site in brain. *J. Neurochem.* **50**:1170-1178.

Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK and Martin BR (2000) O-1057, a potent water-soluble cannabinoid receptor agonist with

antinociceptive properties. *Br. J. Pharmacol.* **129**:1577-1584.

Razdan RK (1986) Structure-activity relationships in cannabinoids. *Pharmacol. Rev.* **38**:75-149.

5 Razdan RK, Terris BZ, Pars HG, Plotnikoff NP, Dodge PW, Dren AT, Kyncl J and Somani P (1976) Drugs derived from cannabinoids: 2. Basic esters of nitrogen and carbocyclic analogs. *J. Med. Chem.* **19**:454-461.

Singer M, Ryan WJ, Saha B, Martin BR and Razdan RK (1998) Potent cyano and carboxamide side-chain analogs of 1',1'-dimethyl- Δ^8 -tetrahydrocannabinol. *J. Med. Chem.* **41**:4400-4407.


10 Zitko BA, Howes JF, Razdan RK, Dalzell BC, Dalzell HC, Sheehan JC and Pars HG (1972) Water-soluble derivatives of Δ^1 -tetrahydrocannabinol. *Science* **177**:442-444.

While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be
15 limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.

CLAIMS

We claim:

1. A water-soluble cannabinoid analog with the general structure



wherein

R_1 is H or a straight-chained, branched or cyclic C_1 - C_6 lower alkyl; and

R_2 is


a 5-7 membered heterocyclic ring in which at least one of the member atoms is N; or

NR_3 where R_3 is H_2 , H_3^+ , or mono or dialkyl C_1 - C_6 ;

or a salt thereof.

2. The cannabinoid analog of claim 1, wherein said 5-7 membered heterocyclic ring is selected from the group consisting of piperidine, methyl piperidine, methyl piperazine and morpholine.


3. A cannabinoid analog with the general structure



wherein R_4 is an azole or morpholine ring,

or a salt thereof.

4. The cannabinoid analog of claim 3, wherein said azole ring is selected from the group consisting of imidazole, 1H-imidazole, methyl imidazole, pyrazole, and triazole.
5. The cannabinoid analog of claim 3, wherein said cannabinoid analog is a water-soluble salt and said azole ring is selected from the group consisting of imidazole 1H-imidazole, methyl imidazole.
6. A cannabinoid analog with the general structure



wherein R_5 is NH_2 , $NHCH_3$, or NHR_6 , where R_6 is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N;


or

wherein R_5 is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N,

or a salt thereof.

7. The cannabinoid analog of claim 6, wherein R_6 is a heterocyclic ring selected from the group consisting of morpholine, homo-piperidine, pyrrolidine, and piperidine.
8. The cannabinoid analog of claim 6, wherein R_5 is a heterocyclic ring selected from the group consisting of morpholine, piperidine, piperazine, pyrrolidine, and homo-piperidine.

9. A water-soluble cannabinoid analog with general structure



wherein

R_7 is H, CH_3 or a straight-chained, branched or cyclic $\text{C}_1\text{-C}_6$ lower alkyl; and

R_8 is

a 5-7 membered heterocyclic ring in which at least one of the member atoms is N; or

NR_3 where R_3 is H_2 , H_3^+ , or mono or dialkyl $\text{C}_1\text{-C}_6$; and


wherein R_9 is NH_2 , NHCH_3 , or NHR_6 , where R_6 is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N;

or


wherein R_9 is a 5-7 membered heterocyclic ring in which at least one of the member atoms is N,

or a salt thereof.

10. The water-soluble cannabinoid analog of claim 9, wherein said analog is



11. A cannabinoid analog with the general structure



wherein

$R_1 = \text{H}, -\text{COCHR}_3-\text{CH}_2-\text{CH}_2-\text{R}_4$;

$R_2 = \text{CN}$ or COR_7 ;

$R_3 = \text{H}$, or a straight-chained, branched or cyclic $\text{C}_1\text{-C}_6$ lower alkyl; and


R_4 and R_7 may be the same or different and are

NH_2 , NHCH_3 , $\text{N}(\text{R}_8)_2$, wherein $\text{R}_8 = \text{COR}_7$;


a 5-7 membered heterocyclic ring with at least one N atom, or

NHR_5 , where R_5 is a 5-7 membered heterocyclic ring with one N atom.

12. The cannabinoid analog of claim 11, wherein said 5-7 membered heterocyclic ring is



13. A method of treating or alleviating symptoms of a disease or disorder associated with CB1 and CB2 cannabinoid receptors in a patient in need thereof, comprising the step of administering to said patient a compound or salt thereof of a general structural formula



wherein

$R_1 = \text{H}, -\text{COCHR}_3-\text{CH}_2-\text{CH}_2-\text{R}_4$;

$R_2 = \text{CN}$ or COR_7 ;

$R_3 = \text{H}$, or a straight-chained, branched or cyclic $\text{C}_1\text{-C}_6$ lower alkyl; and


R_4 and R_7 may be the same or different and are

NH_2 , NHCH_3 , $\text{N}(\text{R}_8)_2$, wherein $\text{R}_8 = \text{COR}_7$;

a 5-7 membered heterocyclic ring with at least one N atom, or

NHR_5 , where R_5 is a 5-7 membered heterocyclic ring with one N atom.

14. The method of claim 13, wherein said 5-7 membered heterocyclic ring is



1/21

Scheme 1




Figure 1

2/21




Figure 2

3/21





Figure 3

4/21

*Figure 4*

5/21

Scheme 5




Figure 5

SUBSTITUTE SHEET (RULE 26)

6/21

Scheme 6




Figure 6

7/21




Figure 7

8/21




Figure 8

9/21





Figure 9


10/21



% Inhibition = % inhibition of spontaneous activity
 % MPE = % maximum antinociceptive effect in tail flick test
 Δ°C = change in rectal temperature
 % Ring Immobility = % time (of 300 s) spent immobile on elevated ring

Figure 10


11/21



% Inhibition = % inhibition of spontaneous activity
 % MPE = % maximum antinociceptive effect in tail flick test
 $\Delta^{\circ}\text{C}$ = change in rectal temperature
 % Ring Immobility = % time (of 300 s) spent immobile on elevated ring

Figure 11

12/21



% Inhibition = % inhibition of spontaneous activity
 % MPE = % maximum antinociceptive effect in tail flick test
 Δ°C = change in rectal temperature
 % Ring Immobility = % time (of 300 s) spent immobile on elevated ring

Figure 12

13/21





Figure 13

14/21



% Inhibition = % inhibition of spontaneous activity
% MPE = % maximum antinociceptive effect in tail flick test
Δ°C = change in rectal temperature
% Ring Immobility = % time (of 300 s) spent immobile on elevated ring

Figure 14

15/21




Figure 15

16/21




Figure 16

17/21





Figure 17


18/21



% Inhibition = % inhibition of spontaneous activity
 % MPE = % maximum antinociceptive effect in tail flick test
 $\Delta^{\circ}\text{C}$ = change in rectal temperature
 % Ring Immobility = % time (of 300 s) spent immobile on elevated ring

Figure 18


19/21



% Inhibition = % inhibition of spontaneous activity
 % MPE = % maximum antinociceptive effect in tail flick test
 $\Delta^{\circ}\text{C}$ = change in rectal temperature
 % Ring Immobility = % time (of 300 s) spent immobile on elevated ring

Figure 19


20/21



% Inhibition = % inhibition of spontaneous activity
 % MPE = % maximum antinociceptive effect in tail flick test
 Δ°C = change in rectal temperature
 % Ring Immobility = % time (of 300 s) spent immobile on elevated ring

Figure 20

21/21



% Inhibition = % inhibition of spontaneous activity
 % MPE = % maximum antinociceptive effect in tail flick test
 $\Delta^{\circ}\text{C}$ = change in rectal temperature
 % Ring Immobility = % time (of 300 s) spent immobile on elevated ring

Figure 21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US05/22178

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 413/06
US CL : 544/150

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 544/150

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ADAMS et al., Journal of the American Chemical Society (1940), 62, 2194-6.	10

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

07 September 2005 (07.09.2005)

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Date of mailing of the international search report

27 SEP 2005

Authorized officer

KAMAL A. SAEED, PH.D.

Rebecca L. Anderson PRIMARY EXAMINER

Telephone No. (571) 272-1600

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US05/22178

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-9 and 11-14
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Please See Continuation Sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

- Remark on Protest**
- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
 - ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
 - ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US05/22178

Continuation of Box II Reason 2:

The numerous variables, e.g. (R1, R2, R3, heterocyclic ring, R4, R5, R6, R7, R8, R9, etc.) and their voluminous, complex meanings and their virtual incomprehensible permutations and combinations make it impossible to determine the full scope and complete meaning of the claimed subject matter. As presented the claimed subject matter cannot be regarded as being a clear and concise description for which protection is sought and as such the listed claims do not comply with the requirements of PCT Article 6. Thus it is impossible to carry out a meaningful search on same. A search will be carried out on the first discernable invention which is the compound of claim 10.

Continuation of B. FIELDS SEARCHED Item 3:

CAS ONLINE

STN structure search